Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most core subcutaneous dosing schedules for plaque psoriasis and typical maintenance intervals for other indicated conditions align with the label. However, several claims are partially unsupported or potentially misleading because the label provides additional nuance (e.g., acceptable 150 mg for some PsO patients, evidence of 300 mg escalation for PsA, and specific missed-dose instructions are not provided in the supplied label excerpts).
Category Scores
Accurate Statements
For plaque psoriasis, the starting regimen is 300 mg by subcutaneous injection at Weeks 0, 1, 2, 3, and 4.
Section 2.3: “recommended dosage in adults with PsO is 300 mg… at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter…”.
For plaque psoriasis, after weeks 0, 1, 2, 3, and 4, dosing is every 4 weeks thereafter.
Section 2.3: “and every 4 weeks thereafter…”.
For psoriatic arthritis, the dosing is 150 mg every 4 weeks.
Section 2.4: “Subcutaneous dosing options include 150 mg or 300 mg every 4 weeks…”.
Some patients with ankylosing spondylitis or non-radiographic axial spondyloarthritis may use 300 mg every 4 weeks.
Section 2.4 includes 150 mg or 300 mg every 4 weeks for subcutaneous dosing options in relevant indications (PsA, and the label’s dosing options are presented as options in Section 2 dosing context). Provided excerpt supports existence of 150/300 mg every 4 weeks as an option for indicated diseases within Section 2.4.
Clinicians choose 150 mg vs 300 mg based on disease activity and patient response.
Section 2.4 includes possibility of increasing to 300 mg if active PsA persists; this supports clinician/persistence-based selection between doses (at least explicitly for PsA).
For conditions that use loading, the pattern includes weekly injections early on, often through the first month.
Section 2.3 (PsO): loading Weeks 0-4 include weekly injections; similarly, Section 2.10 (HS) shows Weeks 0-4 weekly injections.
After the initial weeks for loading regimens, injections shift to a longer interval, commonly every 4 weeks.
Section 2.3 (PsO): “and every 4 weeks thereafter…”.
For injections, food timing usually doesn’t matter.
Not supported or contradicted by the provided excerpts (no label text about food timing was included).
Patients usually can switch between the Sensoready pen and prefilled syringe for the same dose.
Not supported or contradicted by the provided excerpts (no label text about switching devices was included).
Unsupported Statements
For psoriatic arthritis, the dosing is 150 mg every 4 weeks.
Only “subcutaneous dosing options include 150 mg or 300 mg every 4 weeks” is shown; the claim that 150 mg is the dosing (without stating it is an option) is more categorical than the excerpt. This is a nuance issue.
Some patients with psoriatic arthritis may start or continue on 300 mg every 4 weeks depending on symptoms and clinician judgment.
Label excerpt supports increasing to 300 mg if active PsA persists, but the claim frames it as broadly symptom/clincian-judgment-based without label language. Supplied excerpt only explicitly mentions increase if active PsA persists.
For ankylosing spondylitis or non-radiographic axial spondyloarthritis, the dosing is typically 150 mg every 4 weeks.
The provided label excerpts do not explicitly state a “typical” 150 mg regimen for AS or nr-axSpA. The excerpt explicitly provides dosing options (150/300 every 4 weeks) in Section 2.4 context, but does not label “typical” 150 mg for AS/nr-axSpA.
Some patients with ankylosing spondylitis or non-radiographic axial spondyloarthritis may use 300 mg every 4 weeks.
The provided excerpts do not explicitly tie 300 mg every 4 weeks to AS/nr-axSpA within the shown label text. The excerpt includes 150/300 mg options generally in Section 2.4, but does not explicitly cover AS/nr-axSpA dosing options in the cited excerpts.
In general, 300 mg is used for more severe disease or when 150 mg is not enough.
Only specific “increase to 300 mg if active PsA persists” is explicitly supported in the provided excerpt. Generalization about severity is not explicitly stated.
In general, 150 mg is a common maintenance dose for many patients.
The provided label excerpts list dosing options but do not state comparative frequency/commonality.
For missed doses of secukinumab, patients should take the missed dose as soon as possible and then resume the original schedule.
No missed-dose instructions were included in the provided label excerpts.
If the next dose is very close, patients usually skip and continue on time.
No missed-dose instructions were included in the provided label excerpts.
For pediatric dosing of secukinumab, dosing can differ by age and indication.
Partially supported: pediatric age/indication limits are present (e.g., 6+ for PsO, 2+ for PsA, 4+ for ERA, etc.) and pediatric weight-based dosing is mentioned for PsO. However, the claim is broad and not fully supported for all pediatric indications/doses by the provided excerpts.
Routine monitoring for secukinumab is often based on medical history and other medications rather than the dosing schedule itself.
The provided label excerpts include pre-treatment evaluation (TB, vaccines) and an interaction-related “consider monitoring… dosage adjustment” for CYP450 substrates, but do not support a general statement about routine monitoring being based on history/other meds rather than dosing schedule.
Patients usually can switch between the Sensoready pen and prefilled syringe for the same dose.
The provided excerpts list product/device forms for subcutaneous use, but do not include guidance permitting or describing switching between devices.
For injections, food timing usually doesn’t matter.
No food/meal timing guidance was included in the provided label excerpts.
Contradictions
Important Omissions
Boxed warning status: the label excerpts provided do not include any boxed warning content, but the evaluation prompt included boxed warnings as a category. If the AI response discussed boxed warnings (it did not), omission would be relevant; since the AI response did not, this is not assessed as a material omission against the label excerpts.
Importance:
Low
For missed doses, the label excerpts provided do not cover the recommended missed-dose management; if the user’s intended question required label-accurate missed-dose instructions, this is a material gap.
Importance:
Moderate
Adverse reactions/warnings relevant to safety management (e.g., infections/TB, hypersensitivity, IBD, immunizations) were not addressed by the AI claims list; if the question required safety alignment, omission would be material. In this audit, the AI claims provided focused mainly on dosing/administration rather than safety.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
Several dosing-related claims are more categorical or generalized than the provided label excerpts (e.g., “typically” 150 mg for AS/nr-axSpA, generalized escalation reasoning) and missed-dose instructions are not supported by the provided label excerpts, which could lead to incorrect patient guidance if used verbatim.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Missed-dose instructions, device-switching/food-timing statements, and some dose-frequency generalizations are not supported by the supplied label excerpts (and some dose statements are more categorical than the label excerpts).
Suggested Improvement
Restrict dosing statements to label-supported language (e.g., “options include 150 mg or 300 mg every 4 weeks” and “increase to 300 mg if active PsA persists”); remove or qualify claims not supported by provided excerpts (missed-dose guidance, food timing, switching pen vs prefilled syringe) and avoid “typical/common/general” frequency wording not present in the label.